Active Specific Immunotherapy (ASI) in Cancer Treatment: Five Case Reports*Corresponding Author: Shing Yi Pan, Academic Board Advisor and Program Facilitator, European Wellness Academy, Klosterstraße 205, 67480 Edenkoben, Germany, Tel: +60143708083, Email: [email protected]
Received Date: Jul 27, 2019 / Accepted Date: Sep 09, 2019 / Published Date: Sep 16, 2019
Citation: Moya R, Chan MKS, Wong MBF, Klokol D, Chia YC, et al. (2019) Active Specific Immunotherapy (ASI) in Cancer Treatment: Five Case Reports. J Cancer Sci Ther 11: 256-259DOI: 1948-5956
Copyright: © 2019 Moya R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Immunotherapy, including the complementary immunotherapy for cancer, can be categorized as either specific or nonspecific, both with the aim to enhance the immunity against tumors. A proper immunotherapy approach must address a patient’s individual features of complexity such as tumor’s immune suppressive and pro-inflammatory aspects, antigen heterogeneity and immunogenicity. The Active Specific Immunotherapy (ASI) is capable of rearming and boosting the immune system against cancer by exclusively regulating patient’s own immune-modulatory molecules. This article presents five distinct clinical reports of cancer patients that have undergone the ASI treatment, combined with ozone therapy, vitamins infusion and several programs of chemotherapies. As a result, the ASI improved the immune status of all patients and their overall life quality by reducing pain, fatigue and infections recurrences. Furthermore, the ASI treatment did not cause any negative side effects nor interfere whatsoever with the chemotherapy protocol. In conclusion, although further studies are urgently required in the field, ASI offers an interesting and safe strategy as integrative personalized immunotherapy.